INFINI is a clinically proven micro needling fractional RF advice for a wide range of aesthetic indications.
INFINI, developed by Lutronic and distributed in Australia by Advanced Cosmeceuticals, combines radiofrequency energy and microneedling to achieve significant skin rejuvenation, and improvement of photoaged skin and acne scarring.
The dual benefits of RF energy and microneedling are widely reported. This synergistic combination of technology has been reported to help achieve three-dimensional tightening of the skin(1) and reduce the appearance of pigmentation, wrinkles and laxity.
According to an article in the Journal of Cutaneous and Aesthetic Surgery, microneedling fractional radiofrequency (MFR) works by creating RF thermal zones without epidermal injury. This damage to the reticular dermis results in long-term dermal remodelling, neoelastogenesis, neocollagenesis and dermal thickening.
The RF energy is delivered via insulated gold-coated microneedles to create controllable and fractionated coagulation zones within specific layers of the dermis. This level of control means INFINI can be used to successfully treat all skin types, year round, with minimal risk of post – inflammatory hyperpigmentation when performed correctly.
INFINI affords the practitioner complete control over treatment depth and energy levels, enabling a multi-layered, targeted and customisable approach.
80% improvement in acne scarring
A study published in the Journal of Cutaneous and Aesthetic Surgery evaluated results with MFR over a one-year period in 31 patients of skin type III-V with Grade 3 and 4 atrophic acne scars (as measured by Goodman & Baron’s acne scar grading system).
Each patient received four sequential fractional RF treatments over a six-month period with six weeks before each treatment.The results were graded at the end of three months after the last session.
The study found that 80.64 percent of patients showed improvement by two grades, and 19.35 percent showed improvement by one grade. With regards to quantitative assessment, the results showed that 58 percent of the patients had moderate improvement, 29 percent had minimal, nine per cent had good and three per cent showed very good improvement.
A novel approach for axillary hyperhidrosis
A recent study has shown that MRF energy can also specifically affect the sweat glands, while preserving the skin’s surface.
The study, Efficacy of Fractional Microneedle Radiofrequency Device in the Treatment of Primary Axillary Hyperhidrosis: A Pilot Study enlisted 20 patients with primary axillary hyperhidrosis to have two sessions of bipolar MRF at four-week intervals. The results were measured using a Hyperhidrosis Disease Severity Scale (HDSS) and photographs with a starch-iodine test were taken at every visit and two months after the last treatment.
“HDSS scores decreased significantly from a baseline of 3.3 to 1.5 and 1.8 after the first and second months of post-treatment follow-up sessions, respectively (P < 0.001),” the report states.
“In response to a subjective assessment at one month after the second treatment, 75 percent of patients had an HDSS score of 1 or 2, and 70 percent of patients expressed more than 50 percent of improvement in their sweating. The starch-iodine reaction was also remarkably reduced in 95 percent of patients after MRF treatment.”
Histological measurements also showed a decrease in the number and size of apocrine and eccrine glands one month after the final treatment.
Periorbital rejuvenation: long-term improvement with MFR
The combination of microneedling and radiofrequency energy has shown significant promise for improving both static and dynamic wrinkles around the eye area. In older patients particularly, prominent static wrinkles due to photoageing are less responsive to botulinum toxin alone. This is one area where the potential of MRF can be realised.
A recent study compared MFR therapy with intradermal botulinum toxin A (BoNT/A) injections in periorbital rejuvenation. The study, published in Dermatology enrolled twelve women aged 20-59 years in a split faced trial. The participants received one intradermal injection of BoNT/A on the left periorbital area and three sessions of MFR on the right. Each MFR treatment was performed at a depth of 0.5mm to 80ms with a 150W (level 6) intensity for two passes.
Results were measured at baseline and at three, six and 18 weeks following treatment. Photographs of both sides of periorbital areas were taken using identical settings and wrinkle grade and skin elasticity were evaluated.
The results showed all subjects achieved meaningful improvement in periorbital wrinkles with both treatments at final follow-up. On the BoNT/A injection side, the effect was remarkable at three and six weeks. On the MRF treatment side, the effect was unremarkable at three weeks, but showed gradual improvement at six weeks and at the final follow-up. There was no significant difference in patient satisfaction between the two sides at 18 weeks.
The proven clinical studies back the innovative technology behind INFINI, with easy-to-perform procedures and effective outcomes that benefit both patient and practitioner.
Why INFINI?
• 3-dimensional volumising wrinkle reduction
• Treats all skin types, including tanned skin
• Reproducible results
• Clinically proven, with thousands of procedures performed worldwide
• Easy to use, fast procedure
• Specifically targets defined depths with precise coagulation
• Deeper tissue effect than traditional RD and fractional laser
• ComfortFlow technology treats over 3.5mm deep
• Quick and easy recovery with little downtime
• 2 in 1 expandable platform: MFR & SFR
For more information call 1800 242 011, email admin@advancedcosmeceuticals.com.au or visit www.advancedcosmeceuticals.com.au
1. The Asian Aesthetic Guide – Autumn 2011, Dr Pradnya Kulkarni
